Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    adu-cl-11
Previous Study | Return to List | Next Study

Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer (SEASCAPE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02575807
Recruitment Status : Terminated (Study was stopped due to low enrollment and lack of clinical activity.)
First Posted : October 15, 2015
Results First Posted : April 4, 2019
Last Update Posted : April 4, 2019
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
Aduro Biotech, Inc.

Brief Summary:
This 2-part, Phase 1/2 study will test investigational cancer drugs known as CRS-207, epacadostat (IDO), and pembrolizumab (pembro). The purpose of this study is to find out how safe it is to give the investigational drugs to women with platinum-resistant ovarian, fallopian tube, or peritoneal cancer and if it helps patients with these types of cancer live longer or can help shrink or slow the growth of cancer.

Condition or disease Intervention/treatment Phase
Platinum-resistant Ovarian Cancer Platinum-resistant Fallopian Cancer Platinum-resistant Peritoneal Cancer Biological: CRS-207 Drug: Epacadostat Biological: Pembrolizumab Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Actual Study Start Date : March 8, 2016
Actual Primary Completion Date : April 26, 2018
Actual Study Completion Date : May 8, 2018


Arm Intervention/treatment
Experimental: Phase 1: CRS-207

CRS-207 administered in 3-week cycles.

* CRS-207 (1 x 10e9 colony forming units [CFU]) administered by intravenous (IV) infusion. For Cycle 1 through Cycle 6, CRS-207 will be administered on Day 1 of each cycle. After 6 cycles, CRS-207 will be administered on Day 1 once every 6 weeks (every other cycle).

Biological: CRS-207
via IV infusion
Other Name: Live, attenuated double-deleted Listeria monocytogenes (LADD)

Experimental: Phase 1: CRS-207/IDO 100 mg

CRS-207 administered in 3-week cycles, IDO administered twice daily (BID).

  • CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).
  • IDO (100 milligrams [mg]) administered by mouth (PO) BID, starting on Day 2 of the first CRS-207 treatment cycle.
Biological: CRS-207
via IV infusion
Other Name: Live, attenuated double-deleted Listeria monocytogenes (LADD)

Drug: Epacadostat
PO BID
Other Names:
  • INCB024360
  • IDO

Experimental: Phase 1: CRS-207/IDO 300 mg

CRS-207 administered in 3-week cycles, IDO administered BID.

  • CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).
  • IDO (300 mg) administered PO BID, starting on Day 2 of the first CRS-207 treatment cycle.
Biological: CRS-207
via IV infusion
Other Name: Live, attenuated double-deleted Listeria monocytogenes (LADD)

Drug: Epacadostat
PO BID
Other Names:
  • INCB024360
  • IDO

Experimental: Phase 2: CRS-207/Pembro/IDO

CRS-207 and pembrolizumab (pembro) administered in 3-week cycles, IDO administered BID.

  • CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).
  • Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles.
  • IDO (300 mg) administered PO BID, starting on Day 3 of the first CRS-207 treatment cycle.
Biological: CRS-207
via IV infusion
Other Name: Live, attenuated double-deleted Listeria monocytogenes (LADD)

Drug: Epacadostat
PO BID
Other Names:
  • INCB024360
  • IDO

Biological: Pembrolizumab
via IV infusion
Other Names:
  • Keytruda®
  • Pembro

Experimental: Phase 2: CRS-207/Pembro

CRS-207 and pembro administered in 3-week cycles.

  • CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).
  • Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles.
Biological: CRS-207
via IV infusion
Other Name: Live, attenuated double-deleted Listeria monocytogenes (LADD)

Biological: Pembrolizumab
via IV infusion
Other Names:
  • Keytruda®
  • Pembro




Primary Outcome Measures :
  1. Phase 1: Number of Subjects Reporting Hematologic and/or Non-hematologic Dose-limiting Toxicity (DLT) [ Time Frame: Subjects followed for DLTs for 21 days following the first dose of CRS-207 (treatment Cycle 1 for CRS-207). ]

    Count of subjects in the Phase 1 cohorts who reported a hematologic and/or non-hematologic DLT. Non-hematological DLTs are defined as follows, excluding the safety events specified for exemption in Section 5.3.1 of the study protocol:

    • any treatment-emergent adverse event (TEAE) not attributable to disease or disease-related processes that occurs during the DLT observation period (Cycle 1) and is Grade 3 or higher according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4;
    • any use of systemic steroids; and/or
    • a study drug dose interruption lasting ≥ 7 days for an adverse event with an unclear relationship to study drug.

    Hematological DLTs are defined as:

    • Grade 4 neutropenia lasting >7 days;
    • Grade ≥3 febrile neutropenia;
    • Grade 4 anemia;
    • Grade 4 thrombocytopenia or ≥ Grade 3 thrombocytopenia lasting >7 days or associated with bleeding; and/or
    • Dose delay >7 days secondary to myelosuppression.

  2. Phase 1: Adverse Events (AEs) by CTCAE Grade 3 or Higher [ Time Frame: Subjects followed from the start of study treatment until 30 days following the final dose of study drug, an average of 3 months. ]
    Count of subjects in the Phase 1 cohorts with incidences of CTCAE Grade 3 or higher AEs.

  3. Phase 2: Adverse Events (AEs) [ Time Frame: Subjects followed from the start of study treatment until 30 days following the final dose of study drug, an average of 2 months. ]
    Count of subjects in the Phase 2 cohorts with incidences of AEs.

  4. Phase 2: Objective Response Rate (ORR) [ Time Frame: BOR was assessed from the first dose of study treatment until documented disease progression, initiation of a new cancer treatment, death, or study termination, whichever comes first, assessed up to 20 weeks. ]
    ORR was evaluated for Phase 2 subjects based upon the best overall response (BOR) for individual study subjects. BOR was determined by the highest post-baseline qualitative response value for each assessed subject as measured by modified response evaluation criteria in solid tumors (mRECIST) and given the following hierarchy of overall response results: complete response (CR) > partial response (PR) > stable disease (SD) > progressive disease (PD) > not evaluable (NE). The protocol-specified ORR was defined as the percentage of evaluable subjects with a BOR of CR or PR; however, this percentage was not calculated per the final study Statistical Analysis Plan (SAP). Therefore, the number of evaluable subjects with BOR mRECIST values of CR, PR, SD, PD, and NE are provided for this outcome measure.

  5. Phase 2: Progression Free Survival (PFS) [ Time Frame: Subjects followed for disease progression from first dose of study treatment until 30 days after last dose of study treatment or initiation of new cancer treatment, whichever comes first, assessed up to 20 weeks. ]
    Number of weeks from the date of first dose of study treatment to the first date of objectively determined progressive disease (PD) or death from any cause, estimated using Kaplan-Meier (KM) methods with 95% confidence intervals (CIs). PD is determined by mRECIST.


Secondary Outcome Measures :
  1. Phase 1: Objective Response Rate (ORR) by mRECIST [ Time Frame: BOR was assessed from the first dose of study treatment until documented disease progression, starting of a new cancer treatment, death, or study termination, whichever is earlier, assessed up to 100 weeks. ]
    ORR was evaluated for Phase 1 subjects based upon the best overall response (BOR) for individual study subjects. BOR was determined by the highest post-baseline qualitative response value for each assessed subject as measured by modified response evaluation criteria in solid tumors (mRECIST), RECIST v1.1, and GCIG CA-125 criteria and given the following hierarchy of overall response results: complete response (CR) > partial response (PR) > stable disease (SD) > progressive disease (PD) > not evaluable (NE). The protocol-specified ORR was defined as the percentage of evaluable subjects with a BOR of CR or PR; however, this percentage was not calculated per the final study Statistical Analysis Plan (SAP). Therefore, the number of evaluable subjects with BOR mRECIST values of CR, PR, SD, PD, and NE are provided for this outcome measure.

  2. Phase 1: Progression Free Survival (PFS) [ Time Frame: Subjects followed for disease progression from first dose of study treatment until 30 days after last dose of study treatment or initiation of new cancer treatment, whichever comes first, assessed up to 100 weeks ]
    Number of weeks from the date of first dose of study treatment to the first date of objectively determined progressive disease (PD) or death due to any cause, estimated using Kaplan-Meier (KM) methods with 95% confidence intervals (CIs). PD is determined by mRECIST, RECIST v1.1, and GCIG CA-125.

  3. Disease Control Rate (DCR) [ Time Frame: BOR was assessed from the first dose of study treatment until documented disease progression, starting of a new cancer treatment, death, or study termination, whichever comes first, assessed up to 100 weeks. ]
    The protocol-specified DCR was defined as the percentage of evaluable subjects with a BOR of CR or PR, or SD as determined by mRECIST, RECIST v1.1, and GCIG CA-125 criteria.

  4. Duration of Response (DOR) [ Time Frame: Subjects followed for disease progression from date of CR or PR designation until documented disease progression or study termination, whichever comes first, assessed up to 100 weeks. ]
    Number of weeks from date of CR or PR designation until PD designation, as determined by mRECIST, RECIST v1.1 and GCIG CA-125 criteria.

  5. Overall Survival (OS) [ Time Frame: OS was assessed from the first dose of study treatment until death or study termination, whichever comes first, assessed up to 100 weeks. ]
    Number of weeks from the date of first dose of study treatment to the date of death from any cause, estimated using KM methods with 95% CIs for subjects in the SAF. Subjects without documentation of death at the time of analysis were censored as of the date the subject was last known to be alive. For subjects lost to follow up, the last visit or last contact date where the subject is documented to be alive will be used to estimate last known date alive.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically-confirmed disease

    • Phase 1: Individuals with epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinomas who are considered to have platinum-resistant disease (progression within 6 months from completion of platinum-based chemotherapy).
    • Phase 2: Individuals with epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinomas who are considered to have platinum-resistant disease (progression within 6 months from completion of a minimum of 4 platinum therapy cycles).
  2. Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  3. Agree to provide core biopsies at baseline and at Cycle 2 Day 15
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  5. Available archived tumor tissue for central analysis
  6. Adequate organ and marrow function

Exclusion Criteria

  1. Platinum-refractory disease (progression during the first platinum-based chemotherapy)
  2. Major surgical procedure within 4 weeks prior to Study Day 1
  3. Inaccessible tumors or for whom biopsy is contraindicated
  4. Clinically significant ascites
  5. Phase 2 only: Previous treatment with >3 chemotherapy regimens for locally advanced or metastatic disease
  6. Active bowel obstruction, or hospitalization for bowel obstruction within 2 months prior to screening
  7. Require parenteral nutrition
  8. Hospitalization within 2 weeks prior to screening
  9. Received any anticancer medication or therapy in the 21 days prior to study Day 1
  10. Prior monoclonal antibody treatment within 4 weeks before study Day 1
  11. History of listeriosis or previous treatment with a listeria-based immunotherapy
  12. Known allergy to both penicillin and sulfa antibiotics
  13. Any immunodeficiency disease or immune-compromised state
  14. Received prior immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, anti PDL-1) and any other antibody or drug specifically targeting T-cell costimulation or an IDO inhibitor
  15. Pregnant or breastfeeding
  16. Clinically significant heart disease
  17. Valvular heart disease that requires antibiotic prophylaxis for prevention of endocarditis
  18. History of any autoimmune disease which required systemic therapy in the past 2 years
  19. Diagnosed with another malignancy within the past 3 years
  20. Currently receiving therapy with a UDP-glucuronosyltransferase 1A9 inhibitor including diclofenac, imipramine, ketoconazole, mefenamic acid, and probenecid
  21. Receiving monoamine oxidase inhibitor (MAOIs) or a drug which has significant MAOI activity (meperidine, linezolid, methylene blue) within the 21 days before screening
  22. Had prior serotonin syndrome
  23. Has implanted medical devices that pose high risks for colonization and cannot be easily removed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02575807


Locations
Layout table for location information
United States, Arizona
Scottsdale Healthcare Hospitals DBA HonorHealth
Scottsdale, Arizona, United States, 85258
United States, California
Stanford Cancer Center
Stanford, California, United States, 94305
United States, Florida
University of Florida
Gainesville, Florida, United States, 32610
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21287
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
United States, Pennsylvania
University of Pennsylvania Health System
Philadelphia, Pennsylvania, United States, 19104
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
United States, Virginia
University of Virginia Health System
Charlottesville, Virginia, United States, 22903
United States, Washington
Virginia Mason Medical Center
Seattle, Washington, United States, 98101
Canada, Ontario
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
CHUM - Centre Hospitalier de l'Université de Montréal
Montréal, Quebec, Canada, H2X 0A9
Sponsors and Collaborators
Aduro Biotech, Inc.
Incyte Corporation
  Study Documents (Full-Text)

Documents provided by Aduro Biotech, Inc.:
Study Protocol  [PDF] February 18, 2017
Statistical Analysis Plan  [PDF] May 3, 2018


Layout table for additonal information
Responsible Party: Aduro Biotech, Inc.
ClinicalTrials.gov Identifier: NCT02575807     History of Changes
Other Study ID Numbers: ADU-CL-11
First Posted: October 15, 2015    Key Record Dates
Results First Posted: April 4, 2019
Last Update Posted: April 4, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Aduro Biotech, Inc.:
Ovarian cancer
Fallopian cancer
Primary peritoneal cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Peritoneal Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents